Osteopore Ltd (ASX: OSX) Share Price and News

Price

$0.016

Movement

0.001 (-5.88%)

as at 5 May - Closed (20 mins delayed)

52 Week Range

$0.012 - $0.37

 
1 Year Return

-95.73%

Osteopore Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $2.44 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 152.22 million
Earnings per share -0.043
Dividend per share N/A
Year To Date Return -51.43%
Earnings Yield N/A
Franking -
Share Price

$0.016

Day Change

0.001 (-5.88%)

52 Week Range

$0.012 - $0.37

Yesterday's Close

$0.017

Today's Open

$0.018

Days Range

$0.016 - $0.018

Volume

1,245,841

Avg. Volume (1 month)

7,390,856

Turnover

$20,884

as at 5 May - Closed

Osteopore Ltd (ASX: OSX)
Latest News

Three healthcare workers look and point at at medical image
Healthcare Shares

Osteopore (ASX:OSX) share price rockets 24% on major new deal

This healthcare company is having a good day on the ASX today

Read more »

asx medical share price represented by x-ray or people shaking hands
Share Market News

Osteopore (ASX:OSX) share price moving higher on distribution deal

The Osteopore share price has moved higher today on news of distribution deal. This will see its products promoted into Germany…

Read more »

soaring hydrix share price represented by doctor riding on top of heart high up in the clouds
Investing

Why I think these small cap ASX shares will perform in 2021

The ASX is littered with lots of companies that show potential to become the next market darling. Here are my…

Read more »

man using 3d printer
Share Market News

ASX medical share surges 30% on development news

This ASX medical share surged more than 30% after announcing an agreement with QUT on potentially revolutionary 3D technology.

Read more »

Share Market News

2 breakthrough ASX healthcare shares

Australia has helped shape modern medicine in many ways. These 2 ASX healthcare shares are breakthrough companies with strong momentum.

Read more »

Female Archer Materials staffer standing in front of computerised images
Investing

3 innovative ASX shares to buy

Here's a closer look at 3 innovative ASX shares to buy to capitalise on Australian innovation, including Electro Optic Systems…

Read more »

Rocket launching into space
Share Market News

Osteopore share price storms 270% higher on distribution deal

The Osteopore Ltd (ASX: OSX) share price was up more than 260% at one point today, after the company signed…

Read more »

OSX ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
5th May 2025 2025-05-05T18:19:48 Change in substantial holdingYesNo6:19pm31.1M
1st May 2025 2025-05-01T11:27:30 Change in substantial holdingYesNo11:27am3752k
30th Apr 2025 2025-04-30T17:26:40 Notice of Annual General MeetingYesNo5:26pm231M
29th Apr 2025 2025-04-29T08:22:11 Activities Report March 2025 and Appendix 4CYesNo8:22am176.1M
28th Apr 2025 2025-04-28T19:10:13 Change in substantial holdingYesNo7:10pm31M
28th Apr 2025 2025-04-28T18:53:07 Application for quotation of securities - OSXYesNo6:53pm616k
23rd Apr 2025 2025-04-23T18:21:38 Change in substantial holdingYesNo6:21pm3882k
23rd Apr 2025 2025-04-23T18:16:33 Application for quotation of securities - OSXYesNo6:16pm616k
17th Apr 2025 2025-04-17T18:02:40 Change in substantial holdingYesNo6:02pm3885k
15th Apr 2025 2025-04-15T18:20:03 Change in substantial holdingYesNo6:20pm3909k

About Osteopore Ltd

Osteopore Ltd is engaged in the production of 3D-printed bioresorbable implants that are used in conjunction with surgical procedures to assist bone healing. Its products include Osteoplug, which is a bioresorbable implant used for covering trephination burr holes in neurosurgery, and Osteomesh which is a bioresorbable implant used in craniofacial surgery. Business operating segments are based on the firm's geographical presence in Singapore and Australia.

OSX Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
02 May 2025 $0.02 $0.00 0.00% 1,015,613 $0.02 $0.02 $0.02
01 May 2025 $0.02 $0.00 0.00% 2,218,757 $0.02 $0.02 $0.02
30 Apr 2025 $0.02 $0.01 66.67% 4,540,326 $0.02 $0.02 $0.02
29 Apr 2025 $0.02 $0.00 0.00% 4,014,321 $0.02 $0.02 $0.02
28 Apr 2025 $0.02 $0.00 0.00% 6,504,654 $0.02 $0.02 $0.02
24 Apr 2025 $0.02 $0.00 0.00% 1,354,279 $0.02 $0.02 $0.02
23 Apr 2025 $0.02 $0.00 0.00% 778,930 $0.02 $0.02 $0.02
22 Apr 2025 $0.02 $0.00 0.00% 1,411,146 $0.02 $0.02 $0.02
17 Apr 2025 $0.02 $0.00 0.00% 1,770,680 $0.02 $0.02 $0.02
16 Apr 2025 $0.02 $0.00 0.00% 1,954,256 $0.03 $0.03 $0.02
15 Apr 2025 $0.02 $0.00 0.00% 1,718,677 $0.03 $0.03 $0.02
14 Apr 2025 $0.02 $0.00 0.00% 3,784,561 $0.03 $0.03 $0.02
11 Apr 2025 $0.03 $-0.01 -29.41% 10,480,161 $0.03 $0.03 $0.03
10 Apr 2025 $0.03 $0.00 0.00% 20,221,212 $0.04 $0.04 $0.03
09 Apr 2025 $0.03 $0.02 125.00% 62,507,912 $0.04 $0.05 $0.03

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
08 May 2024 Mark Leong Issued 125,000 $3,625
Rights issue.
08 May 2024 Mark Leong Issued 25,000 $3,125
Rights issue.
08 May 2024 Swee Hin Teoh Issued 584,897 $16,962
Rights issue.
08 May 2024 Swee Hin Teoh Issued 116,979 $14,622
Rights issue.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Mark Kei Wei Leong Executive ChairmanExecutive Director Aug 2021
Mr Leong has corporate, management and directorship experience in a range of functions in a diverse range of industries having undertaken several C suite roles (CEO, COO, & CFO) in several private as well as listed companies. He Holds Directorships as Non Executive Director of MDR Limited (SGX:Y3D), Non Executive Director of HS Optimus Holdings Limited (SGX:504), Non Executive Director of 9R Limited (SGX:1Y1) Non Executive Director of LMIRT Management Ltd (SGX:D5IU), Non Executive Director of CytoMed Therapeutics Limited (NASDAQ: GDTC). He held directorships Non Executive Director of LCT Holdings Limited (SGX: delisted December 2020) Executive Director of LifeBrandz Ltd (SGX: 1D3).
Professor Swee Hin Teoh Non-Executive Director Jun 2019
Mr Teoh is currently the Founding Director and Distinguished Yule Chair Professor, Center for Advanced Medical Engineering (CAME) at the College of Materials Science and Engineering, Hunan University, China. He is Emeritus Professor at School of Chemical and Biomedical Engineering (SCBE) and held joint appointment with the Lee Kong Chian School of Medicine (LKC Med) at Nanyang Technological University (NTU). His contribution is in the development and clinical translation of 3D bioresorbable scaffolds. his research journey focused on translating the materials research to biomedical benefits. He is a Fellow of the Academy of Engineers Singapore and Chief Engineer at Skin Research Institute of Singapore. His research focused on the study of mechanisms that promote cells proliferation and differentiation as a result of mechano induction through load bearing scaffolds for tissue regeneration and remodelling. Presently, he focuses on regenerative medicine research from tissue engineering bone and skin to biomimetic bioreactors to fish collagen, decellularized organs and others. With more than 37 PhDs, 270 research publications and 22 patents and technical disclosures, he is a forerunner and excellent educator in bioengineering and research scientist in translational regenerative medicine.
Mr Daniel Ow Non-Executive Director Oct 2021
Mr Ow has accumulated more than twenty years of international experience spanning various industries, such as infrastructure, resources, property, and fast moving consumer goods. Throughout his career, he has undertaken several finance and management positions within multinational corporations. Presently, Mr Ow holds the role of Chief Financial Officer at Greenpool Capital, a fully integrated property investment, asset, and development firm. In addition to his professional endeavors, he has also served as a Trustee Director on the Rio Tinto Staff Superannuation Fund, which has since merged with Equip Super.
Hon Michael Keenan Non-Executive Director Jul 2023
Mr Keenan is a former Australian Government Cabinet Minister and brings invaluable expertise in public policy and corporate governance. He served as a Federal Member of Parliament from 2004 to 2019, holding senior ministry positions in the Abbott, Turnbull, and Morrison Governments between 2013 to 2019. His ministerial portfolios included Human Services, where he provided direction and oversight of Medicare, as well as Justice, Counter Terrorism, and Digital Transformation. Notably, Mr. Keenan also serves on the Board of U Group and Co, as well as the Australian Strategic Policy Institute.
Dr Yujing Lim Chief Executive OfficerExecutive Director Jul 2023
--
Mr Jack Rosagro Company Secretary May 2024
-
Jack Rosagro Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Citicorp Nominees Pty Limited 989,564 9.58%
Bnp Paribas Noms Pty Ltd Uobkh A/C R'Miers 703,551 6.81%
Ms Irene Ng Ai Chen 658,833 6.38%
Mr Patrick John Mchale 500,000 4.84%
Hsbc Custody Nominees (Australia) Limited 328,433 3.18%
Mr Michael Marcus Liew 301,730 2.92%
Mr Evan Philip Clucas & Ms Leanne Jane Weston <Kuranga Nursery Super A/C> 297,624 2.88%
Ching Yuan Huang 280,769 2.72%
Lim Thiam Chye 245,116 2.37%
Dietmar Hutmacher 214,234 2.07%
Bnp Paribas Noms Pty Ltd 212,939 2.06%
Ho Chwan Investment Co Ltd 210,577 2.04%
Mr Hanry Yu 210,371 2.04%
Dr Russell Kay Hancock 200,000 1.94%
Merrill Lynch (Australia) Nominees Pty Limited 170,278 1.65%
Mr Kelvin Chua Yong Wei 165,883 1.61%
Mr Lim Jing 157,334 1.52%
Annika Walter Schantz 139,800 1.35%
Bnp Paribas Noms Pty Ltd Uob Kh Pl Ac 104,451 1.01%
Round Table Partners Berhad 102,300 0.99%

Profile

since

Note